May 7, 2007 Stereotaxis Inc. announced today that it has developed an innovative new single-screen user interface that provides an unprecedented level of interventional lab integration. The product, Odyssey, is a proprietary Stereotaxis design that consolidates multiple information sources and screens within an electrophysiology interventional lab into a single visual display.
Typically, interventional physicians are faced with the challenge of interacting simultaneously with multiple systems and screens, and diverse sources of diagnostic and imaging information during a procedure. Odyssey consolidates all these sources of information into a single, manageable format, dramatically simplifying the interventional lab and potentially bringing greater simplicity and efficiency to electrophysiology procedures.
Odyssey installations will be connected through Global Crossing's worldwide IP Virtual Private Network (VPN) Service to a remote Clinical Services Center, located at Stereotaxis Headquarters in St. Louis, MO. The Clinical Services Center will enable Stereotaxis to remotely support clinical procedures, providing customers with on demand technical support and training at the touch of a button from their lab.
For the first time, diagnostic and imaging information will be available remotely, enabling Stereotaxis to deliver unprecedented levels of customer support. In combination, the Odyssey consolidated visual display, private network, and remote Clinical Services Center are expected to uniquely position Stereotaxis to provide a comprehensively integrated solution to hospitals, potentially improving the efficacy and efficiency of their interventional labs. It is expected that the Odyssey Network will provide a foundation for a family of future networked products and services.
Odyssey has been installed at a number of Stereotaxis clinical
sites, including San Raffaele University Hospital in Milan, Italy, and the University of Ottawa Heart Institute in Ottawa, Canada.
For more information visit www.stereotaxis.com.
February 02, 2024 
